Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas

Oncology Reports

Volumn 11, Issue 2, 2004, Pages 421-426

  Taguchi, Takahide ^a   Kato, Yasumasa ^a,b   Baba, Yuh ^a   Nishimura, Goshi ^a   Tanigaki, Yuji ^a   Horiuchi, Choichi ^a   Mochimatsu, Idumi ^a   Tsukuda, Mamoru ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAGAWA DENTAL COLLEGE   (Japan)

Author keywords

Bax; Chemotherapy; Cyclin E; Head and neck cancer; p21; p27

Indexed keywords

BAX PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN E; CYCLINE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; ONCOPROTEIN; P27 ANTIGEN; PACLITAXEL; PRIMER DNA; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; VINCRISTINE;

AGED; ARTICLE; CANCER STAGING; CELL CYCLE G1 PHASE; CELL SURVIVAL; DRUG EFFECT; GENETICS; HEAD AND NECK TUMOR; HUMAN; METABOLISM; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

AGED; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CISPLATIN; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA PRIMERS; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; G1 PHASE; HEAD AND NECK NEOPLASMS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE;

EID: 3242796014     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.2.421     Document Type: Article

References (34)

1. Worm J, Bartkova J, Kirkin AF, Straten PT, Zeuthen J, Bartek J and Guldberg P: Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene 19: 5111-5115, 2000.
2. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993. (Pubitemid 23346378)
3. Lane DP: p53, guardian of the genome. Nature 358: 15-16, 1992.
4. Qin LF and Ng IO: Exogenous expression of p21 WAF1/CIP1 exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett 172: 7-15, 2001. (Pubitemid 32823467)
5. Radosevic N, Delmer A, Tang R, Marie JP and Ajchenbaum-Cymbalista F: Cell cycle regulatory protein expression in fresh acute myeloid leukemia cells and after drug exposure. Leukemia 15: 559-566, 2001. (Pubitemid 32266722)
6. Smith ML and Seo YR: Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations. Anticancer Res 20: 2537-2539, 2000. (Pubitemid 30614464)
7. Guo B, Cao S, Toth K, Azrak RG and Rustum YM: Overexpression of Bax enhanced antitumor activity of chemotherapeutic agents in head and neck squamous cell carcinoma. Clin Cancer Res 6: 718-724, 2000. (Pubitemid 30111498)
8. Wang X, Masters JR, Wong YC, Lo AK and Tsao SW: Mechanism of differential sensitivity to cysplatin in nasopharyngeal carcinoma cells. Anticancer Res 21: 403-408, 2001. (Pubitemid 32267674)
9. Strobel T, Swanson L, Korsmeyer S and Cannistra SA: BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Prac Natl Acad Sci USA 93: 14094-14099, 1996. (Pubitemid 26424251)
10. Mochimatsu I, Tsukuda M, Furukawa S, Watanabe S, Kubota A and Yanoma S: The sensitivity of head and neck squamous cell carcinomas to tumor necrosis factor-alpha. Biotherapy 6: 239-244, 1993. (Pubitemid 24084943)
11. Baba Y, Tsukuda M, Kagata H, Kato Y and Nagashima Y: Alteration of p16INK4a and cyclin D1 in head and neck carcinoma cell lines. Med Sci Res 27: 479-484, 1999.
12. Gannon JV, Greaves R, Iggo R and Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutation form. EMBO J 9: 1595-1602, 1990.
13. Stephen CW and Lane DP: Mutation conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol 225: 577-583, 1992.
14. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
15. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993. (Pubitemid 23259742)
16. Kawakami K, Tsukuda M, Mizuno H, Nishimura G, Ishii A and Hamajima K: Alteration of the Bcl-2/Bax status of head and neck cancer cell lines by chemotherapeutic agents. Anticancer Res 19: 3927-3932, 1999.
17. Fan S, El-Diery WS, Bae IJF, et al: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824-5830, 1994.
18. Yang B, Eshleman JR, Berger NA and Markowitz SD: Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 2: 1649-1657, 1996. (Pubitemid 26356347)
19. Nakashima T and Clayman GL: Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 126: 957-961, 2000. (Pubitemid 30658294)
20. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T and Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557, 1995.
21. Deng C, Zhang P, Harper JW, Elledge SJ and Leder P: Mice lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684, 1995.
22. Haldar S, Jena N and Croce CM: Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
23. Kuwahara D, Tsutsumi K, Kobayashi T, Hasunuma T and Nishioka K: Caspase-9 regulates cisplatin-induced apoptosis in human head and neck squamous cell carcinoma cells. Cancer Lett 148: 65-71, 2000. (Pubitemid 30012130)
24. Xie X, Clausen OP and Boysen M: Prognostic significance of p21WAF1/CIP1 expression in tongue squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 128: 897-902, 2002. (Pubitemid 34856258)
25. Mineta H, Miura K, Suzuki I, Takebayashi S, Misawa K, Ueda Y and Ichimura K: p27 expression correlates with prognosis in patients with hypopharyngeal cancer. Anticancer Res 19: 4407-4412, 1999. (Pubitemid 30042798)
26. Mineta H, Miura K, Suzuki I, et al: Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer 85: 1011-1017, 1999. (Pubitemid 29115577)
27. Fan GK, Fujieda S, Sunaga H, Tsuzuki H, Ito N and Saito H: Expression of protein p27 is associated with progression and prognosis in laryngeal cancer. Laryngoscope 109: 815-820, 1999. (Pubitemid 29227933)
28. Xie X, Clausen OP, Angelis PD and Boysen M: The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 86: 913-920, 1999. (Pubitemid 29439843)
29. Bandou N, Hayashi T, Kishibe K, Takahara M, Imada M, Nonaka S and Harabuchi Y: Prognostic value of p53 mutation, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma. Cancer 94: 1968-1980, 2002. (Pubitemid 34270050)
30. Dong Y, Sui L, Tai Y, Sugimoto K, Hirao T and Tokuda M: Prognostic significance of cyclin E overexpression in laryngeal squamous cell carcinomas. Clin Cancer Res 6: 4253-4258, 2000.
31. Polyak K, Lee MH, Erdjument-Bromage A, et al: Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66 1994.
32. Parker SB, Eichele G, Zhang P, et al: p53-independent expression of p21 Cip1 in muscle and other terminally differentiating cells. Science 267: 1024-1027, 1995.
33. Donaldson KL, Goolsby GL and Wahl AF: Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 57: 847-855, 1994. (Pubitemid 24216822)
34. Furukawa S, Tsukuda M, Mochimatsu I, Kokatsu T, Satoh H and Sakumoto M: Modified combination chemotherapy of cisplatin and 5-fluorouracil in squamous cell carcinomas of the head and neck. Auris Nasus Larynx 21: 181-185, 1994. (Pubitemid 24335249)